Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The family of deceased rock star Prince is suing a doctor they said prescribed pain pills, claiming the physician did not treat him for opiate addiction and bears some responsibility for his April 2016 death.
Gene therapy company bluebird bio and cancer immunotherapy company Gritstone Oncology are working together to research, develop and produce a cancer treatment product that will use cell therapy.
Using electronic stimulation, researchers were able to stimulate the recovery of neuron cells grown in a petri dish—a method they hope individuals can use while recovering from traumatic brain injuries (TBIs).
Earlier this month, the FDA approved a contraception app for smartphones that claims to help users prevent pregnancy by monitoring body temperature and menstrual cycles. But critics are questioning the FDA’s move, pointing out that dozens of users got pregnant while using the app.
U.S. aircraft maker Lockheed Martin and Australian software developer ResApp Health are collaborating to develop an app that will tell pilots if they’re fit to fly based on the sound of their cough, according to a report by Business Insider Australia.
When a medical device is recalled, the “why,” in the most general terms, is obvious—something is defective. But new research further examines what goes into recall decisions, finding product managers often rely on physicians to find problems with devices. Additionally, device suppliers can be less likely to issue a recall until the cause of the defect is discovered, which can reduce recall costs.
When compared to an FDA-regulated baby monitor, two smartphone-integrated consumer monitors performed inconsistently and displayed incorrectly low pulse rates, according to a Aug. 21 research letter published in JAMA.
